[SCHEDULE 13G/A] Akero Therapeutics, Inc. SEC Filing
RTW Investments, LP and Roderick Wong reported beneficial ownership of 5,873,308 shares of Akero Therapeutics, representing 7.3% of the outstanding common stock. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power recorded.
The percentage is calculated using 79,717,570 shares outstanding as reported by the company. The filing is an amendment to a Schedule 13G and discloses that the RTW Funds hold the right to receive dividends or sale proceeds on the reported shares.
RTW Investments, LP e Roderick Wong hanno dichiarato la titolarit脿 effettiva di 5,873,308 azioni di Akero Therapeutics, pari al 7.3% del capitale sociale in circolazione. La partecipazione 猫 segnalata con potere di voto condiviso e potere di disposizione condiviso, senza alcun potere di voto o di disposizione in via esclusiva.
La percentuale 猫 calcolata utilizzando 79,717,570 azioni in circolazione come riportato dalla societ脿. La comunicazione 猫 un emendamento al Schedule 13G e indica che i fondi RTW hanno il diritto di ricevere dividendi o proventi di vendita sulle azioni dichiarate.
RTW Investments, LP y Roderick Wong informaron la tenencia beneficiaria de 5,873,308 acciones de Akero Therapeutics, que representan el 7.3% del capital social en circulaci贸n. La participaci贸n se reporta con derecho de voto compartido y poder de disposici贸n compartido, sin ning煤n derecho de voto o de disposici贸n exclusivo.
El porcentaje se calcula usando 79,717,570 acciones en circulaci贸n, seg煤n lo informado por la empresa. La presentaci贸n es una enmienda al Schedule 13G y revela que los fondos RTW tienen derecho a recibir dividendos o el producto de la venta de las acciones informadas.
RTW Investments, LP鞕� Roderick Wong電� Akero Therapeutics鞚� 鞁れ 氤挫湢欤检嫕 5,873,308欤�(氚滍枆欤检嫕鞚� 7.3%)毳� 鞁犼碃頄堨姷雼堧嫟. 氤挫湢電� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇溂搿� 鞁犼碃霅橃棃鞙茧┌ 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 鞐嗢姷雼堧嫟.
頃措嫻 牍勳湪鞚� 須岇偓臧� 氤搓碃頃� 氚滍枆欤检嫕靾� 79,717,570欤茧ゼ 旮办鞙茧 靷办稖霅橃棃鞀惦媹雼�. 鞚措矆 鞝滌稖鞚� Schedule 13G鞚� 靾橃爼靹滌澊氅� RTW 韼�霌滉皜 頃措嫻 氤搓碃 欤检嫕鞐� 雽�頃� 氚半嫻旮� 霕愲姅 毵り皝雽�旮堨潉 氚涭潉 甓岆Μ臧� 鞛堨潓鞚� 瓿店皽頃橁碃 鞛堨姷雼堧嫟.
RTW Investments, LP et Roderick Wong ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 5,873,308 actions d'Akero Therapeutics, repr茅sentant 7.3% du capital social en circulation. La d茅tention est d茅clar茅e avec pouvoir de vote conjoint et pouvoir de disposition conjoint, sans pouvoir de vote ni pouvoir de disposition exclusif.
Le pourcentage est calcul茅 en utilisant les 79,717,570 actions en circulation d茅clar茅es par la soci茅t茅. Le d茅p么t constitue un amendement au Schedule 13G et r茅v猫le que les fonds RTW ont le droit de recevoir les dividendes ou le produit de la vente des actions d茅clar茅es.
RTW Investments, LP und Roderick Wong meldeten wirtschaftliches Eigentum an 5,873,308 Aktien von Akero Therapeutics, was 7.3% des ausstehenden Stammkapitals entspricht. Das Eigentum wird als gemeinschaftliches Stimm- und Verf眉gungsrecht angegeben; ein alleiniges Stimm- oder Verf眉gungsrecht wird nicht ausgewiesen.
Die Prozentangabe basiert auf den von der Gesellschaft gemeldeten 79,717,570 ausstehenden Aktien. Die Einreichung ist eine 脛nderung zu einem Schedule 13G und gibt an, dass die RTW-Fonds das Recht haben, Dividenden oder Verkaufserl枚se aus den gemeldeten Aktien zu erhalten.
- Material disclosure: RTW Investments and Roderick Wong report ownership of 5,873,308 shares, equal to 7.3% of AKRO.
- Clear voting status: Filing specifies shared voting and shared dispositive power and 0 sole voting/dispositive power.
- Disclosure basis provided: Percentage calculated using 79,717,570 shares outstanding (company report).
- Filed as Schedule 13G/A (Amendment): indicates compliance with beneficial ownership reporting requirements.
- None.
Insights
TL;DR: RTW holds a material passive stake of 7.3% in AKRO; disclosure clarifies voting and dispositive arrangements.
RTW Investments and Dr. Roderick Wong report a 5,873,308-share position in Akero, equal to 7.3% of the class on a 79.7M-share base. The Schedule 13G/A format signals a non-control, passive investment rather than an activist intent, since the filing states the shares are held in the ordinary course of business and not to influence control. This is materially significant because stakes above 5% must be disclosed and can attract market attention, but the filing itself does not indicate operational or strategic changes. Impact assessment: impactful (disclosure-level).
TL;DR: A disclosed 7.3% shared stake indicates material ownership without sole control; governance influence appears limited by filing language.
The filing specifies shared voting and shared dispositive power for the reported shares and explicitly records 0 shares of sole voting or dispositive power. The certification in Item 10 affirms the position is held in the ordinary course and not intended to change control. From a governance perspective, this clarifies that while RTW has meaningful economic exposure, the filing does not assert control rights or an intent to pursue board or management changes. Impact assessment: impactful (material disclosure, non-control).
RTW Investments, LP e Roderick Wong hanno dichiarato la titolarit脿 effettiva di 5,873,308 azioni di Akero Therapeutics, pari al 7.3% del capitale sociale in circolazione. La partecipazione 猫 segnalata con potere di voto condiviso e potere di disposizione condiviso, senza alcun potere di voto o di disposizione in via esclusiva.
La percentuale 猫 calcolata utilizzando 79,717,570 azioni in circolazione come riportato dalla societ脿. La comunicazione 猫 un emendamento al Schedule 13G e indica che i fondi RTW hanno il diritto di ricevere dividendi o proventi di vendita sulle azioni dichiarate.
RTW Investments, LP y Roderick Wong informaron la tenencia beneficiaria de 5,873,308 acciones de Akero Therapeutics, que representan el 7.3% del capital social en circulaci贸n. La participaci贸n se reporta con derecho de voto compartido y poder de disposici贸n compartido, sin ning煤n derecho de voto o de disposici贸n exclusivo.
El porcentaje se calcula usando 79,717,570 acciones en circulaci贸n, seg煤n lo informado por la empresa. La presentaci贸n es una enmienda al Schedule 13G y revela que los fondos RTW tienen derecho a recibir dividendos o el producto de la venta de las acciones informadas.
RTW Investments, LP鞕� Roderick Wong電� Akero Therapeutics鞚� 鞁れ 氤挫湢欤检嫕 5,873,308欤�(氚滍枆欤检嫕鞚� 7.3%)毳� 鞁犼碃頄堨姷雼堧嫟. 氤挫湢電� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇溂搿� 鞁犼碃霅橃棃鞙茧┌ 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 鞐嗢姷雼堧嫟.
頃措嫻 牍勳湪鞚� 須岇偓臧� 氤搓碃頃� 氚滍枆欤检嫕靾� 79,717,570欤茧ゼ 旮办鞙茧 靷办稖霅橃棃鞀惦媹雼�. 鞚措矆 鞝滌稖鞚� Schedule 13G鞚� 靾橃爼靹滌澊氅� RTW 韼�霌滉皜 頃措嫻 氤搓碃 欤检嫕鞐� 雽�頃� 氚半嫻旮� 霕愲姅 毵り皝雽�旮堨潉 氚涭潉 甓岆Μ臧� 鞛堨潓鞚� 瓿店皽頃橁碃 鞛堨姷雼堧嫟.
RTW Investments, LP et Roderick Wong ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 5,873,308 actions d'Akero Therapeutics, repr茅sentant 7.3% du capital social en circulation. La d茅tention est d茅clar茅e avec pouvoir de vote conjoint et pouvoir de disposition conjoint, sans pouvoir de vote ni pouvoir de disposition exclusif.
Le pourcentage est calcul茅 en utilisant les 79,717,570 actions en circulation d茅clar茅es par la soci茅t茅. Le d茅p么t constitue un amendement au Schedule 13G et r茅v猫le que les fonds RTW ont le droit de recevoir les dividendes ou le produit de la vente des actions d茅clar茅es.
RTW Investments, LP und Roderick Wong meldeten wirtschaftliches Eigentum an 5,873,308 Aktien von Akero Therapeutics, was 7.3% des ausstehenden Stammkapitals entspricht. Das Eigentum wird als gemeinschaftliches Stimm- und Verf眉gungsrecht angegeben; ein alleiniges Stimm- oder Verf眉gungsrecht wird nicht ausgewiesen.
Die Prozentangabe basiert auf den von der Gesellschaft gemeldeten 79,717,570 ausstehenden Aktien. Die Einreichung ist eine 脛nderung zu einem Schedule 13G und gibt an, dass die RTW-Fonds das Recht haben, Dividenden oder Verkaufserl枚se aus den gemeldeten Aktien zu erhalten.
FAQ
How many AKRO shares does RTW Investments report owning?
What percentage of AKRO does the 5,873,308 shares represent?
What voting and dispositive powers are reported for the AKRO shares?
On what share count is the 7.3% calculation based?
Does the Schedule 13G/A indicate RTW intends to influence control of AKRO?
